CStone to Showcase Three ADC Pipeline Programs at 2026 AACR Meeting

CStone Pharmaceuticals ( (HK:2616) ) just unveiled an announcement.

CStone Pharmaceuticals said preclinical data from three proprietary antibody-drug conjugate candidates have been selected for poster presentations at the 2026 American Association for Cancer Research Annual Meeting in San Diego. The assets include CS5007, a potential best-in-class EGFR/HER3 bispecific ADC for multiple solid tumors, CS5008, a novel SSTR2/DLL3 bispecific ADC for small cell lung cancer and neuroendocrine tumors, and CS5006, a potential first-in-class ITGB4-targeting ADC with a wide therapeutic window.

The AACR inclusion underscores CStone’s growing R&D capabilities in next-generation ADCs and supports its strategy to build a differentiated oncology pipeline. Showcasing these preclinical programs on a major global stage may enhance the company’s scientific profile, attract potential partners, and lay groundwork for future clinical development and commercialization efforts.

The most recent analyst rating on (HK:2616) stock is a Sell with a HK$5.00 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.

More about CStone Pharmaceuticals

CStone Pharmaceuticals is a Hong Kong-listed, innovation-driven biopharmaceutical company founded in 2015 and focused on oncology, autoimmune/inflammatory, and other major diseases. The company has launched four innovative drugs, obtained 20 new drug application approvals across nine indications, and is advancing a pipeline of 16 candidates including ADCs, multispecific antibodies, immunotherapies, and precision medicines for China and global markets.

Average Trading Volume: 9,652,431

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$10.35B

Find detailed analytics on 2616 stock on TipRanks’ Stock Analysis page.